NCT06057922 2026-03-12
A Study YL201 in Patients With Selected Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Active not recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Ascentage Pharma Group Inc.
Shanghai Institute Of Biological Products
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Sichuan Huiyu Pharmaceutical Co., Ltd
Affimed GmbH
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nanjing Leads Biolabs Co.,Ltd